Development, verification, and comparison of a risk stratification model to identify potential population benefiting from chemotherapy in non-metastatic male breast cancer

开发、验证和比较风险分层模型,以识别非转移性男性乳腺癌中可能从化疗中获益的人群

阅读:1

Abstract

To establish a prognostic stratification nomogram for non-metastatic male breast cancer to determine which patients can benefit from chemotherapy. A population-based study was conducted using data collected from the surveillance, epidemiology, and end results database. Cox proportional hazards analysis identified significant prognostic factors for survival. A prognostic stratification model was developed using R software. Propensity score matching was implemented to balance characteristics between the chemotherapy cohort and the non-chemotherapy cohort. The multivariate analyses indicated that age, race, grade, surgery, primary tumor, marital status, T stage, and N stage were independent prognostic factors for overall survival in non-metastatic metastatic MBC patients who did not receive chemotherapy (all P < 0.05). The C-index was 0.786 (95% CI 0.662-0.870) in the training cohort and 0.763 (95% CI 0.517-0.852) in the validation cohort. The nomogram effectively discriminated between low-risk, moderate-risk, and high-risk groups concerning OS (P < 0.0001). The current study developed the first prognostic stratification nomogram for non-metastatic MBC and identified that patients in the moderate-risk and high-risk groups are more likely to benefit from chemotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。